0.9703561494	atrial fibrillation
0.9618549541	sick sinus syndrome
0.9606055732	ejection fraction
0.9604201944	phrenic nerve
0.9571817437	myocardial infarction
0.9560098859	magnetic resonance
0.9522880314	heart failure
0.9520752280	informed consent
0.9500649514	beta blocker
0.9484025716	united states
0.9464696225	aortic valve
0.9445343218	congestive heart failure
0.9431474344	valvular heart disease
0.9424082654	blood pressure
0.9415789108	beta blockers
0.9405500956	life expectancy
0.9370671086	sinus rhythm
0.9369406418	magnetic resonance imaging
0.9349947379	gold standard
0.9349822799	implantable cardioverter defibrillator
0.9344963499	american heart association
0.9323175619	cardiopulmonary bypass
0.9319476191	mitral valve
0.9318133765	sudden cardiac death
0.9299600765	statistical analysis
0.9287955473	coronary sinus
0.9277225124	sample size
0.9252330272	coronary artery disease
0.9245018320	aortic stenosis
0.9232955445	acute kidney injury
0.9230212900	subclavian vein
0.9227734061	sleep apnea
0.9201490449	mri scan
0.9189491728	chagas disease
0.9185485442	heart rate
0.9166700610	dilated cardiomyopathy
0.9140973947	general anesthesia
0.9139083749	adverse event
0.9138447983	qrs complex
0.9136808404	clinical trial
0.9132522246	sinus node
0.9119472408	left bundle branch
0.9088592734	adverse events
0.9082375672	public health
0.9051973830	scar tissue
0.9042736429	local anesthesia
0.9028738410	vital signs
0.9026429817	cardiac surgery
0.9022577324	congenital heart disease
0.9002727826	exclusion criteria
0.8999943262	atrioventricular block
0.8984233076	cardiac arrest
0.8971369468	radiation exposure
0.8968921737	left ventricle
0.8963691906	bundle branch block
0.8946872034	atrial flutter
0.8937555459	steering committee
0.8925458587	left ventricular
0.8914193123	monitoring station
0.8914153050	cardiac output
0.8864920107	anti inflammatory
0.8850131651	heart rate variability
0.8838156477	health care
0.8836408722	cognitive function
0.8828559800	heart disease
0.8808910914	physical activity
0.8804513360	pulmonary vein isolation
0.8791640550	randomly assigned
0.8779547701	minimally invasive
0.8775637272	primary safety endpoint
0.8771216995	holter monitor
0.8764396773	eligibility criteria
0.8751564429	data analysis
0.8746342921	secondary endpoints
0.8721604408	end points
0.8718977382	heart valve
0.8683322863	edwards sapien
0.8682802651	ventricular tachycardia
0.8675062487	randomized controlled trial
0.8660556983	meta analysis
0.8657613330	paravalvular leakage
0.8656465287	natriuretic peptide
0.8652142291	tricuspid regurgitation
0.8628161159	coronary artery bypass
0.8613859759	clinical trials
0.8608909871	av delay
0.8598129688	inclusion criteria
0.8572296535	chest pain
0.8569904034	acurate neo
0.8555702618	clinical research
0.8555100520	implantable cardioverter defibrillators
0.8549956648	cardiac resynchronisation therapy
0.8543067558	pulmonary veins
0.8541900583	transthoracic echocardiography
0.8516446832	observational study
0.8501166275	scopeguide Â®
0.8492301815	qrs duration
0.8487506836	double blind
0.8471704281	atrio ventricular
0.8461908393	written informed consent
0.8453671743	pulmonary vein
0.8452128031	cardiac resynchronization therapy
0.8446703068	secondary objectives
0.8445644863	beats min
0.8428852710	fdg pet
0.8409609509	surgical aortic valve replacement
0.8386180810	implantable cardioverter
0.8382503424	open label
0.8379725566	aortic valve stenosis
0.8374461243	transcatheter aortic valve implantation
0.8369061901	electrical cardioversion
0.8366681025	persistent af
0.8345287044	stroke volume
0.8335019628	vasovagal syncope
0.8332103473	mitral regurgitation
0.8316162094	coronary angiography
0.8312091311	sacral nerve
0.8310730884	prosthetic material
0.8308403843	dp dt
0.8303436577	dual chamber
0.8298229069	primary endpoint
0.8291382747	patient population
0.8290109210	kaplan meier
0.8289774613	t1 mapping
0.8288002357	data collection
0.8284812918	pet ct
0.8282455332	integrated pet mri
0.8266163625	sinus node dysfunction
0.8257781574	mg kg
0.8252649159	medical history
0.8247479424	clinical practice
0.8236074226	medical therapy
0.8201957263	diagnostic yield
0.8194146916	life threatening
0.8194062786	outdoor exposure
0.8175401957	follow ups
0.8172033975	study design
0.8158620843	oxygen consumption
0.8152622067	antiarrhythmic drugs
0.8148603567	exercise capacity
0.8148386034	patient safety
0.8138238279	phase ii
0.8135683865	heart rhythm
0.8117120197	remote monitoring
0.8105748971	nyha class
0.8104271675	venous access
0.8084739914	study population
0.8084128959	control group
0.8079659395	pet mri
0.8078089666	end point
0.8076317308	hospital stay
0.8075525157	lead extraction
0.8069885815	severe aortic stenosis
0.8063771512	bundle pacing
0.8061909007	blood samples
0.8059673616	healthy controls
0.8052839912	av node
0.8051924778	balloon expandable
0.8035404783	long term
0.8033108757	operating room
0.8031930862	x ray
0.8030205080	ethics committee
0.8017146835	aortic valve replacement
0.8013335560	coronary artery
0.8007732708	transcatheter aortic valve replacement
0.8001177458	primary efficacy endpoint
0.7974424372	ck mb
0.7960385614	left atrium
0.7956366479	anti arrhythmic
0.7956114310	clinical evaluation
0.7953965326	mechanical dyssynchrony
0.7952635642	ventricular pacing
0.7952351113	av block
0.7950171700	catheter ablation
0.7934424372	mann whitney
0.7932726570	electrical activation
0.7929668199	cardioverter defibrillator
0.7928713326	conduction delay
0.7927002400	post implant
0.7912201705	omega 3
0.7909836111	jude medical
0.7905313799	cycle length
0.7901686635	usual care
0.7900628984	sudden death
0.7898633624	heart block
0.7885751194	chagas cardiomyopathy
0.7881482848	cardioverter defibrillators
0.7881150723	pilot study
0.7875930289	rate adaptive
0.7861208052	left ventricular ejection fraction
0.7858752330	written consent
0.7845562752	clinically relevant
0.7831176141	adverse effects
0.7829140066	nt pro bnp
0.7825395543	myocardial injury
0.7825289863	pulse generator
0.7808348803	peri procedural
0.7806516853	functional class
0.7804886017	vascular access
0.7803652828	cardiopulmonary exercise testing
0.7798608199	university hospital
0.7796736640	real world
0.7790651475	beneficial effects
0.7780336245	oropharyngeal scc
0.7779254354	loop recorder
0.7773543400	exposure reduction
0.7772565893	rate responsive
0.7772197728	valve implantation
0.7756239420	mechanical activation
0.7753993161	nt probnp
0.7751076610	oxygen uptake
0.7728432482	cross clamp
0.7726905827	wall motion
0.7722932249	cardiac arrhythmia
0.7719243061	placebo controlled
0.7715241777	conduction disturbances
0.7710925371	pacemaker implantation
0.7694728665	medical records
0.7675679506	significance level
0.7669249778	transcatheter aortic valve
0.7666889964	biventricular pacing
0.7648443624	ultrasound guided
0.7648125130	cardiac mri
0.7644054050	double blinded
0.7628341533	chronotropic incompetence
0.7627417206	multi center
0.7621862652	battery longevity
0.7614399977	short term
0.7604233659	permanent pacemaker
0.7596192185	av node ablation
0.7583525431	phrenic nerve stimulation
0.7565056121	blood flow
0.7560222148	study duration
0.7545613034	fda approved
0.7532327364	device implantation
0.7527739713	home monitoring
0.7526979302	low risk
0.7525401748	exercise tolerance
0.7511517969	av conduction
0.7495796678	heart team
0.7471745771	minnesota living with heart failure
0.7455516488	cohort study
0.7435001972	major adverse
0.7406533552	ecg monitoring
0.7405879088	severe symptomatic aortic stenosis
0.7403199494	myocardial scar
0.7396884503	post market
0.7348237515	primary objective
0.7346993267	end systolic volume
0.7341316239	beats per minute
0.7339822333	single blind
0.7296385198	end diastolic
0.7294228514	hospital discharge
0.7289572614	ventricular arrhythmias
0.7267923683	long standing persistent
0.7251741176	ablation procedure
0.7251139273	lead placement
0.7240461740	rv pacing
0.7226774564	surgical procedure
0.7221818945	cardiovascular events
0.7220190759	intrinsic conduction
0.7206532060	post operative
0.7199174914	heart rates
0.7197035970	st segment
0.7191288434	cardiac implantable electronic
0.7190061947	hour holter monitoring
0.7169121577	left atrial
0.7160441597	risk stratification
0.7123339003	single arm
0.7085605467	left bundle
0.7062494041	walk test
0.7050337604	single chamber
0.7048045340	york heart association
0.7034481252	biventricular pacemaker
0.7030967090	cost effectiveness
0.7023897710	holter monitoring
0.7017196258	electrical activity
0.7000131500	tissue doppler imaging
0.6990530907	single centre
0.6982441936	low dose
0.6911432131	success rate
0.6908497884	valve replacement
0.6888711251	left ventricular function
0.6878975496	cardiac function
0.6863371596	resynchronization therapy
0.6860849149	open heart surgery
0.6843539307	tissue doppler
0.6828958403	cardiovascular disease
0.6807621582	clinical outcomes
0.6798662285	intention to treat
0.6793495447	primary outcome
0.6785649853	af burden
0.6778258984	thromboembolic events
0.6752484395	secondary outcomes
0.6750926170	force frequency
0.6739834381	physiologic pacing
0.6735921168	morbidity and mortality
0.6707487217	mr imaging
0.6705085479	single center
0.6704606435	pacemaker or icd
0.6692631554	quality of life
0.6691438198	exercise testing
0.6691276623	dual chamber pacemaker
0.6690269383	cardiac pacemaker
0.6685414330	high output
0.6683677970	aortic regurgitation
0.6680416866	current guidelines
0.6644956665	lv function
0.6631820822	pre discharge
0.6617512398	surgical risk
0.6601149310	risk factors
0.6580626411	invited to participate
0.6549859451	standard of care
0.6528536284	pacemaker dependent
0.6523988051	tavi procedure
0.6522303327	mass index
0.6508499034	permanent pacemaker implantation
0.6489602333	controlled trial
0.6477530793	exercise test
0.6467391529	treatment group
0.6459257782	performance and mood
0.6453773403	safety and efficacy
0.6441040719	length of stay
0.6438904154	treating physician
0.6438222550	standard care
0.6425238503	efficacy and safety
0.6415129887	clinic visit
0.6406723133	high risk
0.6373458170	kidney injury
0.6371499766	clinical investigation
0.6367980006	pacing mode
0.6357742571	high grade
0.6355726828	ventricular stimulation
0.6344312360	heart muscle
0.6342916031	end systolic
0.6342680032	control arm
0.6323734406	dual chamber pacing
0.6290881179	atrial pacing
0.6289893745	implantable electronic
0.6283883979	rhythm monitoring
0.6283293159	congestive heart
0.6277384934	cardiac monitoring
0.6268649609	study endpoints
0.6261501897	follow up visit
0.6254937656	imaging modality
0.6254745618	lv lead
0.6235888747	pre and post
0.6233022580	specific aim
0.6230869998	moderate to severe
0.6215063884	minute walk
0.6207826541	de novo
0.6198465808	left bundle branch block
0.6192615057	cardiac rhythm
0.6180425372	treatment groups
0.6167505650	patient enrollment
0.6158509809	new york heart association
0.6116335050	consent form
0.6101097066	implantable cardiac
0.6074849267	post procedure
0.6045741140	biv pacing
0.6015448129	right ventricular apex
0.5969639979	patients undergoing
0.5965025038	cardiac pacing
0.5964383357	inclusion and exclusion criteria
0.5956303435	inclusion and exclusion
0.5943269151	post implantation
0.5934564130	implanted device
0.5928794221	atrial tachyarrhythmias
0.5878646885	implant procedure
0.5878455929	ventricular dyssynchrony
0.5861066645	device success
0.5840011625	pacing lead
0.5835818859	safety and effectiveness
0.5823017232	crt implant
0.5812485992	atrial and ventricular
0.5811993570	valve surgery
0.5811446639	randomized trial
0.5801687146	device implant
0.5794669117	response rate
0.5714394427	cardiac devices
0.5704040091	rate control
0.5702868426	pacemaker icd
0.5700436283	systolic dysfunction
0.5690401128	pacemaker implant
0.5675140910	related complications
0.5665065786	pacemaker programming
0.5661106668	patients receiving
0.5656850133	cardiac device
0.5641515248	recent studies
0.5639009559	primary analysis
0.5626912593	early and late
0.5625295999	minute walk test
0.5619349544	device performance
0.5617188699	non inferiority
0.5604145119	lead implantation
0.5602831622	data collected
0.5575499250	medical center
0.5559228659	version 1.1
0.5540612266	clinical study
0.5531117906	minnesota living
0.5528018204	randomized controlled
0.5527396252	selection criteria
0.5523054667	pulmonary function
0.5511079113	heart score
0.5509309711	rate response
0.5508212015	left ventricular dysfunction
0.5507202469	af ablation
0.5500269059	cardiopulmonary exercise
0.5487568832	lead impedance
0.5487272979	new york
0.5449169828	node ablation
0.5446517524	serious adverse events
0.5439253820	symptomatic aortic stenosis
0.5432498957	lead position
0.5408761921	transcatheter aortic
0.5369056933	sf 36
0.5338675001	high dds
0.5329519366	bundle branch
0.5326342413	apical pacing
0.5319036726	intervention group
0.5285818160	high degree
0.5278926932	cardiac resynchronization
0.5272201458	left ventricular lead
0.5269587048	permanent pacing
0.5266957501	left ventricular pacing
0.5251387043	pacemaker clinic
0.5237311284	chronic heart failure
0.5222837580	follow up period
0.5222825280	drug therapy
0.5210982267	heart association
0.5201625138	septal pacing
0.5194751382	minnesota living with heart
0.5193622831	increased risk
0.5164242751	nervous system
0.5156634751	pacemaker therapy
0.5137347743	icd implantation
0.5103269348	ventricular lead
0.5069896109	device interrogation
0.5068400233	crt device
0.5068155842	months post
0.5064507957	pacemaker or defibrillator
0.5052609535	high risk patients
0.5047995824	consecutive patients
0.5042558211	persistent atrial fibrillation
0.5032764549	pacing leads
0.5024657113	g poem
0.5014701252	study procedures
0.5006972975	previous studies
0.4999794092	baseline characteristics
0.4995012533	response to crt
0.4992899685	intervention arm
0.4989028156	blood tests
0.4976640861	eligible patients
0.4974111628	ventricular function
0.4971332473	r wave sensing
0.4961018879	study sites
0.4960940790	continuous variables
0.4958354014	randomized study
0.4956106970	rhythm control
0.4954217384	ddd pacing
0.4943860993	surgical aortic valve
0.4929104865	ventricular septum
0.4922977148	clinical care
0.4920933680	arrhythmic events
0.4912150329	lv pacing
0.4838476144	et al
0.4835736735	ventricular dysfunction
0.4820428875	pacing rate
0.4801672447	left ventricular systolic
0.4801412186	clinical outcome
0.4795337512	ventricular activation
0.4791619138	electronic devices
0.4789678464	normal sinus rhythm
0.4781677193	cardiovascular death
0.4766574764	â¤ 35
0.4763943617	implanted devices
0.4747691724	surgical aortic
0.4745804850	clinical studies
0.4733079702	the present study
0.4695850681	procedure related
0.4673478171	nt pro
0.4664128783	follow up visits
0.4661255765	study aims
0.4611454134	6 minute walk test
0.4608688162	e avr
0.4600795424	pacing sites
0.4585441744	treatment option
0.4569121215	long standing
0.4537820628	prospective study
0.4533168755	rva pacing
0.4522205071	post tavi
0.4507753807	recurrence rate
0.4497938774	study site
0.4437620315	adult patients
0.4427623054	adverse device
0.4398672244	low risk patients
0.4392062937	cardiac ct
0.4374025587	co morbidities
0.4365495979	pacing modes
0.4360134646	rate variability
0.4356792843	pre implant
0.4352322240	higher risk
0.4350713743	lead positioning
0.4294925127	open heart
0.4262273070	patients with chronic heart failure
0.4243780609	clinical data
0.4238648520	limited data
0.4237461057	post procedural
0.4234767098	cardiac amyloid
0.4230941621	crt d
0.4219674114	ventricular ejection fraction
0.4199318673	safety endpoint
0.4183469889	pediatric patients
0.4174793429	y n
0.4170716860	study participants
0.4159277211	structural heart
0.4159052735	clinically significant
0.4144354450	month follow
0.4138858452	artery bypass
0.4128430820	lead ecg
0.4107072399	predictive value
0.4094754644	time frame
0.4091203904	quality of life questionnaire
0.4078180088	functional status
0.4077162642	left ventricular ejection
0.4062847906	month period
0.4062357379	crt p
0.4057643460	non invasively
0.4054967322	high quality
0.4046087454	lv end systolic
0.4045473393	treatment options
0.4039532262	study period
0.4034321003	cross over
0.4000083245	efficacy endpoint
0.3983613843	ventricular apex
0.3978951432	electrical stimulation
0.3977759305	acute coronary
0.3972917824	pre specified
0.3941363087	clinically indicated
0.3905388642	ventricular apical
0.3900475959	patient selection
0.3900137427	sapien 3
0.3884756134	12 lead ecg
0.3880776280	commercially available
0.3877630787	exact test
0.3870339458	hemodynamic parameters
0.3847942841	follow up
0.3846086352	exercise training
0.3824804881	pacing thresholds
0.3815161629	6 minute walk
0.3778701051	research team
0.3776217718	clinical benefit
0.3773021363	coronary intervention
0.3768088122	leadless pacemakers
0.3758442014	patients with sss
0.3749725059	care unit
0.3740513038	implanted pacemaker
0.3739560574	varc 2
0.3737626780	study protocol
0.3736208288	self expanding
0.3715040618	right ventricular pacing
0.3697888302	early and late outcome
0.3689522140	treatment arms
0.3662378880	right ventricle
0.3644535085	twice daily
0.3631484646	nerve stimulation
0.3627768945	chronic heart
0.3571016622	pacemaker device
0.3536650456	device data
0.3483783477	cross over study
0.3482893224	systolic volume
0.3477839181	left and right
0.3441488082	95 ci
0.3428698268	doppler imaging
0.3425044342	right atrium
0.3382416602	r wave
0.3382310486	heart failure patients
0.3372045571	patients with af
0.3372043580	new york heart
0.3371524430	greater than
0.3370741320	12 and 24
0.3367226606	right ventricular
0.3360924984	valvular heart
0.3356545627	patients with severe
0.3354763736	patients with severe symptomatic
0.3350441781	late outcome of tavi
0.3326499097	right and left
0.3319540563	whole body
0.3318018546	48 hours
0.3305609109	aortic valve implantation
0.3299959575	dual chamber pacemakers
0.3295027335	cancer patients
0.3276046976	number of patients
0.3274580208	chf patients
0.3234479668	collect data
0.3230497339	prospective randomized
0.3229517758	advanced heart
0.3222081037	patients with heart failure
0.3211167110	device related
0.3208538463	non responders
0.3187719817	48 hour
0.3179761932	congenital heart
0.3164708686	controlled trials
0.3143646066	n =
0.3143344565	non invasive
0.3126707050	24 hour
0.3119502435	caused by
0.3096597992	take place
0.3050400029	prospective observational
0.3048792963	body mass
0.3038981950	all cause mortality
0.3035545438	device follow up
0.3017257172	prospective cohort
0.2997252364	implanted cardiac
0.2994249892	95 confidence
0.2992265910	after cardiac surgery
0.2991432779	12 months
0.2968377719	the investigators hypothesize
0.2966337309	side effects
0.2939786920	new onset
0.2902763465	group of patients
0.2901640865	cardiac implantable
0.2900467903	routine clinical
0.2895999218	cardiovascular risk
0.2882677142	24 hours
0.2855242537	resynchronisation therapy
0.2846176568	capable of
0.2831697593	depending on
0.2793772192	persistent atrial
0.2778251013	two sided
0.2758339718	intensive care
0.2755020268	severe symptomatic
0.2738607759	most common
0.2732654201	days post
0.2712266567	14 days
0.2661587640	pacemaker patients
0.2660676359	elderly patients
0.2656418427	enrolled patients
0.2648999478	six months
0.2645270764	right atrial
0.2643139390	syncope patients
0.2627592651	widely used
0.2627092502	undergoing tavi
0.2615393678	6 months
0.2601602447	before and after
0.2596512227	nyha functional
0.2588641783	february may
0.2583037229	sub study
0.2576285436	ventricular leads
0.2575939740	valve system
0.2557674993	based on
0.2530642480	month follow up
0.2523278642	branch block
0.2512343649	related adverse
0.2508550946	optimal medical
0.2506746943	living with heart failure
0.2489657393	30 days
0.2487363287	suffering from
0.2471416235	lv end
0.2465544842	standard clinical
0.2461008423	rather than
0.2458425536	so far
0.2452382183	early and late outcome of
0.2421985018	18 years
0.2418280312	7 days
0.2417778220	recent years
0.2404614620	risk patients
0.2400154649	the primary endpoint
0.2389159247	chamber pacemaker
0.2374237915	well established
0.2372100155	less than
0.2371110041	6 month
0.2363808613	in recent years
0.2344869696	real time
0.2336925688	delivery system
0.2328915619	american heart
0.2322410669	defined as
0.2320943107	output pacing
0.2282372081	years old
0.2278809110	first line
0.2256903705	24 months
0.2254532108	time to first
0.2226500326	hf patients
0.2210042936	af patients
0.2188892016	during and after
0.2179176561	study designed to
0.2179085864	risk factors for
0.2178479779	3 months
0.2171216834	as well as
0.2155772005	the site of
0.2154834365	conduction system
0.2131294147	the heart muscle
0.2130267475	patients treated with
0.2128827886	does not
0.2118703866	did not
0.2095960684	the day of
0.2095455891	patients implanted with
0.2073535899	this pilot study
0.2072826018	clinical follow up
0.2055872614	at least
0.2037554224	prior to
0.2036137636	patients with severe aortic
0.2025262974	the basis of
0.2025164700	this study
0.1991977679	the primary outcome
0.1989151863	in contrast to
0.1986165979	increased risk of
0.1982419999	patients with permanent
0.1980836345	due to
0.1954326809	the research team
0.1951476631	with severe aortic
0.1942837606	a variety
0.1937318899	more than
0.1936906138	do not
0.1928291919	the coronary sinus
0.1926101354	6 weeks
0.1923597844	pacemaker implantation in
0.1921043331	accordance with
0.1919899744	in order to
0.1915789977	high risk for
0.1884683367	the left ventricle
0.1883586471	failure questionnaire
0.1881757889	electronic device
0.1877515422	high risk of
0.1876209634	current standard
0.1874825698	in heart failure patients
0.1872335781	a single center
0.1856754335	the changes of
0.1840247775	the primary efficacy
0.1835376993	late outcome
0.1831201493	non ischemic
0.1830014105	or dual chamber
0.1818294270	the force frequency
0.1815405990	every 6 months
0.1811475712	most important
0.1802549409	cardiac resynchronisation
0.1799359540	at rest
0.1797220653	variety of
0.1789908884	patients randomized to
0.1788610812	as soon as
0.1782007896	sudden cardiac
0.1780151111	in accordance
0.1776234949	primary end
0.1767204044	according to
0.1760552522	patients admitted
0.1759645779	in patients with heart failure
0.1749383733	in patients undergoing
0.1749039038	serve as
0.1747290515	one month
0.1740288797	differences between
0.1728114690	the inclusion criteria
0.1722929492	cls on
0.1717427217	to assess
0.1712260550	to evaluate
0.1712247849	patients with implanted
0.1711210930	group 2
0.1705172921	interfere with
0.1698166473	normal sinus
0.1694369844	in sinus rhythm
0.1683888687	late outcome of
0.1679341780	primary efficacy
0.1675884876	regardless of
0.1670736165	non randomized
0.1670492351	study aims to
0.1662815175	4 weeks
0.1659968183	the study period
0.1638613750	include patients
0.1635152617	in terms of
0.1626450982	patients with
0.1619819316	compared to
0.1615300067	such as
0.1535588816	this registry
0.1534381491	the sample size
0.1524947385	5 years
0.1516099219	the control group
0.1498280964	at 30 days
0.1489655998	ventricular end
0.1482900442	18 months
0.1481376200	benefit from
0.1477579908	associated with
0.1468205116	90 days
0.1464178920	2 weeks
0.1463753632	patients treated
0.1455577751	asked to
0.1453910668	artery disease
0.1450384226	with or without
0.1426717993	9 months
0.1425669736	of patients undergoing
0.1417822972	difference between
0.1398136198	determined by
0.1391899939	able to
0.1382616777	to determine
0.1370568658	in europe
0.1367923359	to achieve
0.1366032990	cardiac magnetic
0.1365585488	commonly used
0.1363235781	three months
0.1358745563	lower than
0.1340294659	both groups
0.1340148526	all patients
0.1331542783	two groups
0.1326855188	candidates for
0.1326072122	at 6 months
0.1323354666	group 1
0.1317779798	the primary safety
0.1308646920	the study
0.1305992884	patients with chronic
0.1294094221	the primary objective
0.1293500312	months after
0.1288004678	ventricular function and
0.1283821001	determine whether
0.1280075367	effect on
0.1271116610	after tavr
0.1267683507	with severe symptomatic
0.1264291168	severe aortic
0.1262784541	information about
0.1262701916	with heart failure
0.1259617347	heart surgery
0.1250912899	compared with
0.1240863332	pacing in patients
0.1240431438	an informed consent
0.1237444988	6 and 12 months
0.1236929548	to compare
0.1231985603	a dual chamber
0.1220550112	designed to
0.1219716532	to ensure
0.1218004630	each patient
0.1214557552	serious adverse
0.1214511998	classified as
0.1212952025	the long term
0.1202285149	one week
0.1199051717	data from
0.1183828234	the heart rate
0.1182174112	the steering committee
0.1179289971	each subject
0.1176166110	heart failure with
0.1174645441	lack of
0.1172391624	3 years
0.1168243738	permanent pacemakers
0.1161262438	related to
0.1159972154	to identify
0.1158859109	differences in
0.1157731093	the investigators
0.1156416799	sample size of
0.1153254677	as follows
0.1148437179	to investigate
0.1146666124	all participants
0.1145241995	for heart failure
0.1143712818	through 30 days
0.1133059024	time points
0.1127496373	excluded from
0.1126028196	per minute
0.1125487606	1 month
0.1120649037	the patient
0.1110963471	10 minutes
0.1107627620	performed using
0.1092225831	in addition
0.1084717468	1 ratio
0.1084367320	with respect to
0.1074847646	obtained from
0.1072667111	one year
0.1069998041	an important
0.1060683206	a prospective
0.1059387154	to detect
0.1055655190	30 day
0.1053655087	chamber pacing
0.1049993563	30 minutes
0.1046212241	10 years
0.1035970083	number of
0.1035470487	to perform
0.1018176836	15 day
0.1017080561	an alternative
0.1011961842	results from
0.1009464181	two weeks
0.1002045259	the principal
0.1000847921	before surgery
0.0999309780	effects on
0.0995920965	unable to
0.0989769795	6 minute
0.0989025758	each individual
0.0976812817	the other hand
0.0975624061	consist of
0.0973546984	consisting of
0.0969914519	3 month
0.0962801365	in accordance with
0.0951622795	patients enrolled
0.0933123676	these devices
0.0932748025	the danish
0.0931748021	an independent
0.0928204415	responsible for
0.0927772394	each stage
0.0926107793	these studies
0.0921222518	defined by
0.0920670361	measured by
0.0909705785	to gain
0.0907646886	contribute to
0.0901143070	an absolute
0.0900903635	2 months
0.0900727038	treated with
0.0899458457	the primary objective of
0.0897390313	incidence of
0.0887409569	derived from
0.0882099564	2 years
0.0873861037	with regard to
0.0872183281	implanted pacemakers
0.0871310080	the rv
0.0871240018	in humans
0.0869781150	expected to
0.0869139080	randomized to
0.0866805581	cardiac death
0.0866693738	for example
0.0866368452	eligible for
0.0862839850	to explore
0.0860303670	the investigator
0.0858430030	patients with pacemakers
0.0856064289	by means of
0.0855794508	each group
0.0854708758	to establish
0.0849515128	1 year
0.0849165530	as measured by
0.0848597359	three groups
0.0843571290	exposed to
0.0837613261	in patients with
0.0835746180	to examine
0.0835325425	indication for
0.0832357546	5 months
0.0825626743	all subjects
0.0823557867	recruited from
0.0821240224	to improve
0.0817844949	4 months
0.0817627175	impact on
0.0814854013	considered as
0.0814383423	loss of
0.0813537110	a total of
0.0811011146	these patients
0.0808609191	leading to
0.0806504843	resulting in
0.0803492808	to treat
0.0802134389	history of
0.0796490285	to demonstrate
0.0794747979	obtained by
0.0786564154	randomized into
0.0780632976	hours after
0.0779451502	the purpose of
0.0779228085	collected from
0.0779107326	to minimize
0.0777835023	drug use
0.0776121957	data on
0.0771544484	no longer
0.0770608405	immediately after
0.0770354500	assessed using
0.0770165942	chf due
0.0760501609	associated with increased
0.0755735613	discharged from
0.0754323483	to define
0.0754168828	combined with
0.0741907900	after tavi
0.0739255372	admitted to
0.0737366370	of patients
0.0736780001	to determine whether
0.0736423128	procedure time
0.0727462094	referred to
0.0716205669	a non invasive
0.0715100422	implanted with
0.0714825442	every 6
0.0708473528	occurrence of
0.0703035601	the right ventricle
0.0702852393	proportion of
0.0698075474	an additional
0.0697952843	a single
0.0696043192	result in
0.0692419460	a large
0.0691801517	design of
0.0690827767	this approach
0.0689725579	participation in
0.0686314316	determine if
0.0685768948	5 year
0.0683991784	assessed by
0.0683779135	duration of
0.0683160704	as part of
0.0682319060	identification of
0.0681772644	death from
0.0675421569	from baseline to
0.0673104329	two years
0.0673044799	data regarding
0.0672462264	performed at
0.0672084182	aim of
0.0668400325	the end of
0.0667043192	difference in
0.0664977682	any cause
0.0660497037	change in
0.0659558774	an increased
0.0656139099	safety and efficacy of
0.0651332123	changes in
0.0650102128	and quality of life
0.0649760844	shown to
0.0649678464	discharge from
0.0649376525	reduction in
0.0648861709	linked to
0.0648577911	the heart
0.0645727546	at baseline
0.0644286461	aimed at
0.0644056907	in case of
0.0643666837	information on
0.0643107204	the device
0.0641610928	improvements in
0.0639241679	improvement in
0.0639148289	the ed
0.0639012356	allocated to
0.0633926076	persistent or
0.0631594450	evolution of
0.0628537547	identified as
0.0627447265	as per
0.0626334892	days after
0.0624408775	this trial
0.0622963043	effects of
0.0613882686	designed as
0.0612742067	performed by
0.0611922573	absence of
0.0610513746	in patients with severe
0.0609779787	the same
0.0606594382	presence of
0.0605171879	at least one
0.0601568717	an icd
0.0601304981	enrolled in
0.0600157949	beats per
0.0598238731	evaluation of
0.0591851536	the follow up period
0.0591811273	24 hours after
0.0591096615	followed by
0.0585376649	a pacemaker
0.0585347322	in patients
0.0582994919	the effect of
0.0581967169	programmed to
0.0580277128	two different
0.0578228314	role of
0.0578033150	understanding of
0.0577230440	after surgery
0.0570582566	to prevent
0.0569158713	a minimum of
0.0569158713	to participate in
0.0568988244	the main
0.0567229510	a sample size of
0.0565309332	pacemaker system
0.0562945631	but also
0.0562095710	the use of
0.0561270323	an effective
0.0560562487	the aim of
0.0557340225	any time
0.0554348272	the number of patients
0.0552368993	conducted at
0.0550452063	performed during
0.0550179744	achieved by
0.0549155241	after implantation
0.0546017851	affected by
0.0545015856	the safety of
0.0543637072	led to
0.0541617170	relationship between
0.0541381413	all cause
0.0535167795	all data
0.0535061551	indications for
0.0530645160	this project
0.0527447009	to avoid
0.0527319830	usefulness of
0.0526842999	to reduce
0.0525698152	evaluated by
0.0525608246	in patients with chronic
0.0525487586	as assessed by
0.0525391266	a series of
0.0523119830	attached to
0.0521988618	the procedure
0.0519030915	assigned to
0.0518309841	department of
0.0515677651	to verify
0.0515398000	over time
0.0515246848	the first
0.0514400184	a digital
0.0514326325	risk of
0.0514048353	to predict
0.0509187771	this reason
0.0507543875	subset of
0.0506707685	registered as
0.0505324178	correlate with
0.0503620256	pathophysiology of
0.0503138298	a fixed
0.0502160416	an external
0.0501694007	referred for
0.0501037436	rate of
0.0500286570	day before
0.0498730584	after randomization
0.0497775581	involved in
0.0492923935	a variety of
0.0490570554	other hand
0.0487550067	on exercise
0.0486743019	collected at
0.0485927628	role in
0.0484719830	thought to
0.0484248179	12 lead
0.0474708402	as needed
0.0471923601	children with
0.0471003140	approved by
0.0470765390	12 months after
0.0469842230	subjects with
0.0469665372	the relationship between
0.0468158006	the primary
0.0467680204	this population
0.0465548609	to confirm
0.0464899323	1 ratio to
0.0464719830	declaration of
0.0463546775	treatment with
0.0462618383	safety and effectiveness of
0.0462193170	the past
0.0461714002	the time of
0.0461578719	to document
0.0460815074	collection of
0.0457950444	in turn
0.0452805119	connected to
0.0449948450	at 12 months
0.0449444623	to conduct
0.0447587945	response to
0.0445258340	aiming to
0.0444547866	the safety and effectiveness of
0.0444076535	part of
0.0443946040	the participant
0.0442205119	consistent with
0.0440789192	placed on
0.0439349730	1 year after
0.0439141044	pacing in patients with
0.0438064381	combination of
0.0437003508	the entire
0.0436343476	doses of
0.0435372033	to provide
0.0435105533	to generate
0.0434814820	during surgery
0.0434168336	respect to
0.0433975449	to obtain
0.0433318123	and 12 months
0.0433172117	year follow up
0.0432992279	majority of
0.0432866609	suitable for
0.0431061849	to support
0.0431003140	guided by
0.0430184005	provided by
0.0430114359	increase in
0.0424706095	not yet
0.0423076826	this protocol
0.0422989192	as described
0.0422504201	half of
0.0420221344	implantation of
0.0419881942	to develop
0.0418643374	the quality of life
0.0418118929	management of
0.0417297956	at discharge
0.0414644800	to determine if
0.0412793170	the possibility
0.0412044657	screened for
0.0411238972	from baseline
0.0410638696	to optimize
0.0410283377	completion of
0.0409284927	symptoms of
0.0408491200	and 6 months
0.0407285362	an estimated
0.0407167468	criteria for
0.0407056016	through 30
0.0404339085	to guide
0.0403881942	to enroll
0.0402339901	included in
0.0401637686	amount of
0.0398749212	type of
0.0398204106	to create
0.0396346275	and 5 years
0.0392641297	this research
0.0390812058	opportunity to
0.0390001417	at 1 year
0.0389931393	the presence of
0.0389259559	weeks after
0.0387872344	performed on
0.0387458040	a common
0.0386841751	at risk
0.0386515393	return to
0.0385435769	deterioration of
0.0385148805	an acute
0.0384041878	progression of
0.0383399227	superior to
0.0380605119	advances in
0.0380584981	assessment of
0.0380387309	inferior to
0.0379157342	and 1 year
0.0379144939	diagnosed with
0.0378503911	a small
0.0378346622	living with
0.0377849864	in fact
0.0377539352	the head
0.0377142511	the results of
0.0376480683	treatment for
0.0374976678	blinded to
0.0374604846	a significant
0.0374428691	option for
0.0373953308	the same time
0.0373831608	any other
0.0373666883	used for
0.0369570631	the safety and effectiveness
0.0369285591	association with
0.0369252309	the central
0.0369251141	the world
0.0368887298	an increase in
0.0368401197	types of
0.0367904201	range of
0.0365571300	this prospective
0.0364476457	up to
0.0364089811	for patients
0.0362233937	regard to
0.0361440690	participate in
0.0359369561	a maximum
0.0358347233	access to
0.0353702181	percentage of
0.0352419796	as possible
0.0350461344	the operator
0.0342757552	many patients
0.0340018532	and safety of
0.0336135514	inability to
0.0334631058	as well
0.0332563814	a maximum of
0.0332168323	as soon
0.0331150080	guidelines for
0.0330010850	to receive
0.0328023323	reduction of
0.0327546814	the mechanism
0.0325855962	set to
0.0325651881	centers in
0.0325348402	submitted to
0.0324503167	to facilitate
0.0324304536	level of
0.0323927763	performed in
0.0323542264	to describe
0.0323511591	to collect
0.0323120685	in women
0.0323101667	the need for
0.0322129847	ability to
0.0321620576	this period
0.0320998632	to participate
0.0320534197	development of
0.0319030307	likely to
0.0316521731	100 patients
0.0314615945	to increase
0.0313307571	need for
0.0312829899	for participation
0.0311882519	the start of
0.0311066982	intervention for
0.0309974395	the efficacy of
0.0309175034	the event
0.0308887438	the effectiveness of
0.0308660218	of patients with
0.0308452655	the occurrence of
0.0307096573	discretion of
0.0306313776	6 months after
0.0305128869	the risk of
0.0304701667	the treatment of
0.0303300682	effect of
0.0303269275	within 2
0.0299860570	treatment of
0.0299842363	dose of
0.0299484731	participants with
0.0297148682	a minimum
0.0295234143	performed as
0.0294701667	the incidence of
0.0293140014	in addition to
0.0292628427	period of
0.0292004418	frequency of
0.0290639046	a result
0.0290508137	not only
0.0290505664	implementation of
0.0289579904	the last
0.0289304536	activation of
0.0289251957	scheduled for
0.0289251219	evidence for
0.0288740989	reported to
0.0288043371	into two
0.0287784333	people with
0.0287735954	with preserved
0.0287586899	within 24
0.0286511125	the opportunity
0.0285706280	the effects of
0.0285088338	up period
0.0284196872	limited to
0.0284091271	a standardized
0.0283770492	increases in
0.0283603301	for at least
0.0283225957	analysis of
0.0282985157	attempt to
0.0282390404	a final
0.0281864814	review of
0.0281170047	the ability to
0.0279672853	as measured
0.0278651593	the pathophysiology
0.0276752510	the case of
0.0276031623	years after
0.0275543276	after implant
0.0274727133	detection of
0.0273211160	the benefits of
0.0272889561	used to
0.0272545337	considered to
0.0271072691	risk for
0.0270321578	followed for
0.0268758368	the diagnosis
0.0268585291	the patient's
0.0267301154	efficacy of
0.0267107896	to answer
0.0266675077	therapy for
0.0265810466	decrease in
0.0265650209	end of
0.0265289006	for patients with
0.0264222411	to check
0.0264151743	performance of
0.0264128077	placement of
0.0263843075	length of
0.0263298168	to report
0.0262776378	the development of
0.0261567109	a major
0.0261314478	purpose of
0.0260566866	results in
0.0259616797	in response to
0.0258661804	to date
0.0258565077	comparison of
0.0257229206	the goal of
0.0254094287	but not
0.0253434202	a double
0.0253383925	the quality of
0.0252738364	to complete
0.0252432195	to measure
0.0251651154	evidence of
0.0249874518	diagnosis of
0.0249399227	predictors of
0.0249349657	the patient to
0.0249282468	applied to
0.0247224685	a multicenter
0.0246980548	of cases
0.0246664066	benefit of
0.0245352506	infusion of
0.0244752283	the absence of
0.0244450475	of interest
0.0244004578	of life
0.0243719703	these two
0.0243641439	known as
0.0242776378	the impact of
0.0242466760	patterns of
0.0242136940	to estimate
0.0242117874	the rate of
0.0241867436	the implantation of
0.0240993188	point of
0.0240839709	patients per
0.0240775696	prevention of
0.0240355363	during follow up
0.0239863169	this time
0.0239774601	used in
0.0239479177	used as
0.0238534103	the management of
0.0238307712	invited to
0.0237136940	to sign
0.0236946259	method of
0.0236436793	objective of
0.0235763205	among patients
0.0235413355	the change in
0.0234752283	the diagnosis of
0.0234482712	results of
0.0233184541	the role of
0.0232717893	a strategy
0.0232632331	rates of
0.0231989985	the amount of
0.0231989985	the degree of
0.0231117032	to allow
0.0230863922	seems to
0.0230206828	the duration of
0.0229650663	impact of
0.0228995327	similar to
0.0228824958	quality of
0.0228784541	the number of
0.0228219336	implanted in
0.0227829206	the percentage of
0.0227779507	along with
0.0227533463	at baseline and
0.0227492500	prevalence of
0.0226592909	patients without
0.0226479273	considered in
0.0226229438	administration of
0.0225740989	evaluated in
0.0224582622	cohort of
0.0224479273	characteristics of
0.0221728077	measures of
0.0221565142	use of
0.0221446872	required for
0.0220632331	needed to
0.0220376615	the lack of
0.0220194797	the objective of
0.0220008940	society of
0.0219292466	periods of
0.0218484165	the database
0.0218105029	with respect
0.0217852733	a number of
0.0217829206	the prevalence of
0.0217739979	the majority
0.0217729273	approach for
0.0217640782	randomised to
0.0216861464	the benefit of
0.0216734165	the aim
0.0216336832	accuracy of
0.0215402279	state of
0.0215196872	knowledge of
0.0214937750	well as
0.0214344069	the type of
0.0213869278	course of
0.0212200831	the occurrence
0.0210849990	location of
0.0210120360	severity of
0.0210065361	of latest
0.0209958809	the course of
0.0208593444	as compared to
0.0207736853	of care for
0.0207729273	considered for
0.0206283463	the assessment of
0.0206045940	a reduction
0.0206045664	a novel
0.0204973440	possibility of
0.0204053005	the ability
0.0203522096	hospitalization for
0.0203400831	the effect
0.0202348582	seen at
0.0202253191	least one
0.0202168172	evaluated for
0.0201616797	the identification of
0.0201295290	for outdoor
0.0200413355	the level of
0.0200239179	in case
0.0200229273	sites in
0.0200162891	a range of
0.0199479273	benefits of
0.0197881041	composite of
0.0197735683	center for
0.0197718897	onset of
0.0197651167	the majority of
0.0197239179	in children
0.0196754179	moderate to
0.0195033272	measurement of
0.0194796061	required to
0.0192874530	prognosis of
0.0191728077	improvement of
0.0190617436	a period of
0.0189770140	a retrospective
0.0189719374	same time
0.0189698772	on patients with
0.0189616797	the safety and
0.0188796978	an indication
0.0188521654	the literature
0.0188283463	the analysis of
0.0188233602	difficult to
0.0186861464	a reduction in
0.0186242650	collected in
0.0186128077	episodes of
0.0185608955	levels of
0.0183155947	the purpose
0.0182311635	placed in
0.0182226332	to decrease
0.0182068747	a third
0.0181497257	10 patients
0.0181368054	degree of
0.0181015517	feasibility of
0.0180413355	the feasibility of
0.0179969599	risks of
0.0179032669	made by
0.0178602955	insertion of
0.0178202418	willing to
0.0177735683	outcome of
0.0176213627	choice of
0.0175070182	occur in
0.0174440899	effectiveness of
0.0174124530	aims to
0.0170643132	this pilot
0.0170588969	significance of
0.0170039059	factors for
0.0169318986	conducted in
0.0168153520	and efficacy of
0.0168153520	the evaluation of
0.0166403515	order to
0.0166207706	and effectiveness of
0.0164047138	planned to
0.0161746856	the incidence
0.0161605701	a new
0.0161099319	care for
0.0159491824	to make
0.0157962930	first pacemaker
0.0156965494	every 3
0.0155196872	goal of
0.0152416642	the presence
0.0152411096	and quality of
0.0149229949	time of
0.0148150831	the department
0.0147019962	20 patients
0.0146783017	indicated for
0.0145448262	the progression
0.0144926242	present in
0.0144417387	reported in
0.0141764535	value of
0.0140960189	by means
0.0139980188	series of
0.0139980188	result of
0.0139878704	as compared
0.0139109597	particularly in
0.0138823883	especially in
0.0136892933	the next
0.0135025077	to undergo
0.0134530404	to show
0.0130160978	found to
0.0129306560	to give
0.0128175021	activities of
0.0124570068	known to
0.0123965963	causes of
0.0122721935	necessary to
0.0120673797	subject to
0.0120615523	a second
0.0120388250	done in
0.0119510642	necessary for
0.0119502232	in terms
0.0119303132	outside of
0.0118965963	to take
0.0117980188	case of
0.0117721935	to help
0.0114530404	allow for
0.0111997583	seen in
0.0111593825	minimum of
0.0110343825	means of
0.0109906267	an informed
0.0101993435	the need
0.0097790135	followed at
0.0096137037	an increase
0.0094713212	year after
0.0089168302	terms of
0.0087918302	addition to
0.0087790135	described in
